Abdelrahaman G. Tawfik

Abdelrahaman G. Tawfik

Auto-generated profile, based on publicly available information

Abdelrahaman G. Tawfik

Department of Pharmacotherapy College of Pharmacy, University of Utah Salt Lake City Utah USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
ATAbdelrahman G. Tawfik
Abdelrahman G. Tawfik
AGAinhoa Gomez‐Lumbreras
Ainhoa Gomez‐Lumbreras
GFGuilherme Del Fiol
Guilherme Del Fiol
KKKensaku Kawamoto
Kensaku Kawamoto
KTKaty E. Trinkley
Katy E. Trinkley
DMDaniel C Malone
Daniel C Malone
Nonsteroidal anti‐inflammatory drugs (NSAIDs) are widely used for pain and inflammation but are associated with gastrointestinal (GI) bleeding. While this risk is well established, most studies evaluate NSAIDs as a homogenous class, limiting clinical decision‐making based on individual agent safety. This systematic review and meta‐analysis aimed to quantify the risk of GI bleeding associated with individual NSAIDs. We searched PubMed from inception through January 2025 using MeSH and free‐text terms for “gastrointestinal bleeding” and nine commonly used NSAIDs. A random effects meta‐analysis was conducted to estimate the pooled odds ratios (ORs) for GI bleeding, with hazard ratios (HRs) and relative risks (RRs) treated as approximations of ORs due to the rare event nature of GI bleeding. Of 6,711 records screened, 25 studies met the inclusion criteria. Substantial heterogeneity in study design, populations, and outcome ascertainment was observed. Celecoxib was associated with the lowest risk of GI bleeding (OR 1.16, 95% CI: 0.84–1.61). Among non‐selective NSAIDs, ibuprofen had the lowest significant risk (OR 2.28, 95% CI: 1.71–3.03), while ketorolac showed the highest risk (OR 20.67, 95% CI: 14.56–29.34). Other agents, such as piroxicam and meloxicam, also demonstrated significantly elevated risks. The risk of GI bleeding varies widely among individual NSAIDs. Celecoxib appears to have the lowest GI risk, though cardiovascular safety must also be considered. These findings highlight the need for personalized NSAID selection and suggest that NSAIDs should not be treated as a uniform class when assessing bleeding risk.

4 March 2025 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Open access
TMTrisha Matsuura
Trisha Matsuura
ATAbdelrahaman G. Tawfik
Abdelrahaman G. Tawfik
KBKenechukwu C. Ben-Umeh
Kenechukwu C. Ben-Umeh
PHPhilip D. Hansten
Philip D. Hansten
DMDaniel C Malone
Daniel C Malone
Objective: Hyponatremia is a common electrolyte disorder among older adults that can cause serious adverse effects. The purpose of this study was to assess the risk of hyponatremia with the concurrent use of selective serotonin reuptake inhibitors (SSRIs) and thiazide diuretics in an older population.Methods: Two retrospective nested case–control studies were conducted with exposure to an SSRI or a thiazide diuretic. Persons of interest were those enrolled in Medicare and who received parts A, B, and D benefits from 2017 to 2019 and who were receiving either an SSRI or thiazide diuretic. Cases were individuals with a diagnosis of hyponatremia. Controls had no documented history of hyponatremia. A logistic regression was conducted to determine the odds of hyponatremia.Results: Of the 551,298 patients receiving a SSRIs, the mean age was 77.8 years (Standard Deviation (SD) ± 8.0 years), 69% were female, and 91.23% were classified as White. We identified 701,007 individuals receiving a thiazide diuretic, with a mean age of 77.1 years (SD ± 7.2 years), 60.2% female, and 82.72% White. The prevalence of hyponatremia was 10.4% in patients taking thiazides alone and 9.0% in those taking SSRIs alone. On the other hand, patients on both medications had a hyponatremia prevalence of approximately 13.0%. Among SSRI users, the adjusted odds ratio (OR) of hyponatremia with concomitant use of thiazide diuretics was 1.24 (95% Confidence Interval (CI): 1.22–1.26). For thiazide users, the adjusted OR of hyponatremia with exposure to SSRIs was 1.27 (95% CI:1.24–1.29).Conclusion: The concurrent use of thiazide diuretics and SSRIs is associated with an increased risk of hyponatremia in older populations.

29 December 2025 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
AGAinhoa Gomez‐Lumbreras
Ainhoa Gomez‐Lumbreras
ATAbdelrahman G. Tawfik
Abdelrahman G. Tawfik
GFGuilherme Del Fiol
Guilherme Del Fiol
KKKensaku Kawamoto
Kensaku Kawamoto
ARAnd Thomas J. Reese
And Thomas J. Reese
DMDaniel C Malone
Daniel C Malone
Aim: The purpose of this study is to estimate the risk of gastrointestinal bleeding (GIB) by selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs) individual agents. Methods: A systematic review was conducted for each unique antidepressant (i.e. SSRI: citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline; and SNRIs: desvenlafaxine, venlafaxine, and duloxetine) combined with search terms for GIB in PubMed and EMBASE from inception to October 2025. Articles including results on specific antidepressants and GIB risk were included. Results: From a total of 1218 identified publications, 20 studies were included and analysed using a random‐effect meta‐analysis. Twelve studies (60%) used a case–control design, three (15%) a cohort study design, one (5%) a case cross‐over, one (5%) used both case–control and cross‐over designs and three (15%) were randomized control trials (RCTs). Studies sample sizes ranged from 666 235 from a Medicaid population to 1280 from 43 hospitals participating in a RCT. Fluoxetine had the most studies providing evidence (19 studies) and fluvoxamine and duloxetine had the least (five studies). Each antidepressant showed an increased risk of GIB. Venlafaxine had the highest estimated risk (OR 1.50, 95% CI 1.32–1.70), followed by citalopram (OR 1.38, 95% CI 1.17–1.62) and fluoxetine (OR 1.38, 95% CI 1.26–1.51). Paroxetine had the lowest GIB risk (OR 1.31, 95% CI 1.07–1.62). Conclusion: GIB is an uncommon adverse event, but this analysis demonstrates that the risk of GIB is elevated for commonly used SSRI/SNRI products, highlighting the relevance for those patients with an increased risk of GIB.

1 August 2023 in Canadian Journal of Respiratory Therapy
Verified
Journal Article
Open access
PDF file
YBYasra Badi
Yasra Badi
MHMohamed Hammad
Mohamed Hammad
ATAbdelrahman G. Tawfik
Abdelrahman G. Tawfik
MEMona Muhe Eldeen Eshag
Mona Muhe Eldeen Eshag
MEMahmoud M. Elhady
Mahmoud M. Elhady
AAAhmed Hashem Fathallah Abdelrahman
Ahmed Hashem Fathallah Abdelrahman
Background: More than six million people died due to COVID-19, and 10-15% of infected individuals suffer from post-covid syndrome. Corticosteroids are widely used in the management of severe COVID-19 and post-acute COVID-19 symptoms. This study synthesizes current evidence of the effectiveness of inhaled corticosteroids (ICS) on mortality, hospital length-of-stay (LOS), and improvement of smell scores in patients with COVID-19. Methods: We searched Embase, Web of Science, PubMed, Cochrane Library, and Scopus until Aug 2022. The Cochrane risk of bias tool was used to assess the quality of studies. We evaluated the effectiveness of ICS in COVID-19 patients through measures of mortality, LOS, alleviation of post-acute COVID-19 symptoms, time to sustained self-reported cure, and sense of smell (visual analog scale (VAS)). Results: Ten studies were included in the meta-analysis. Our study showed a significant decrease in the LOS in ICS patients over placebo (MD = -1.52, 95% CI [-2.77 to -0.28], p-value = 0.02). Patients treated with intranasal corticosteroids (INC) showed a significant improvement in VAS smell scores from week three to week four (MD =1.52, 95% CI [0.27 to 2.78], p-value = 0.02), and alleviation of COVID-related symptoms after 14 days (RR = 1.17, 95% CI [1.09 to 1.26], p-value < 0.0001). No significant differences were detected in mortality (RR= 0.69, 95% CI [0.36 to 1.35], p-value = 0.28) and time to sustained self-reported cure (MD = -1.28, 95% CI [-6.77 to 4.20], p-value = 0.65). Conclusion: We concluded that the use of ICS decreased patient LOS and improved COVID-19-related symptoms. INC may have a role in improving the smell score. Therefore, using INC and ICS for two weeks or more may prove beneficial. Current data do not demonstrate an effect on mortality or time to sustained self-reported cure. However, the evidence is inconclusive, and more studies are needed for more precise data.

16 May 2026 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Closed access
ATAbdelrahman G. Tawfik
Abdelrahman G. Tawfik
AGAinhoa Gomez-Lumbreras
Ainhoa Gomez-Lumbreras
SGSpencer J. Gilbert
Spencer J. Gilbert
HHHeeseung Hong
Heeseung Hong
XYXiangyang Ye
Xiangyang Ye
DWDaniel M. Witt
Daniel M. Witt

25 October 2026 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Open access
PDF file
AGAinhoa Gomez‐Lumbreras
Ainhoa Gomez‐Lumbreras
ATAbdelrahman G. Tawfik
Abdelrahman G. Tawfik
ARAnd Thomas J. Reese
And Thomas J. Reese
DWDaniel M. Witt
Daniel M. Witt
GFGuilherme Del Fiol
Guilherme Del Fiol
DMDaniel C Malone
Daniel C Malone
Introduction: Pharmacodynamic drug–drug interactions (DDI) in patients receiving oral anticoagulants (OAC) may increase the risk of gastrointestinal bleeding (GIB). The purpose of this study was to develop and validate a GIB model for patients receiving OACs. Methods: A risk model, D rug I nteractions in O ral A nti C oagulants for Risk of G astro i ntestinal B leeding (DIOAC‐GIB), was developed to predict GIB based on interacting medications and other patient‐specific risk factors for patients on OAC. Inputs for the model were obtained using random‐effect meta‐analysis or from the literature for the following attributes: exposure to nonsteroidal anti‐inflammatory drugs (NSAIDs); selective serotonin reuptake inhibitors/serotonin‐norepinephrine reuptake inhibitors (SSRI/SNRIs); aspirin, antiplatelet medications, and proton pump inhibitors (PPIs); age; and GIB history. The model was correlated to existing OAC models (HAS‐BLED and DOAC score). Results: GIB risk for OACs was based on pivotal trials (1.16% for apixaban; 3.15% for rivaroxaban; 3.00% for dabigatran; 3.31% for edoxaban; and 2.00% for warfarin). The odds ratio (OR) of GIB for NSAIDs ranged from 1.16 (95% confidence interval [CI]: 0.84–1.61) for celecoxib to 20.67 (95% CI: 14.56–29.34) for ketorolac. ORs for GIB among SSRI/SNRIs ranged from 1.31 (95% CI: 1.07–1.62) for paroxetine to 1.50 (95% CI: 1.32–1.70) for venlafaxine. Risk of GIB also included persons > 65 years of age (relative risk = 2.50, 95% CI: 1.2–5.5); history of GIB (OR = 5.14, 95% CI: 3.92–6.73); exposure to aspirin (OR = 1.31, 95% CI: 0.93–1.85), antiplatelet medications (OR = 1.97, 95% CI: 1.73–2.25), and corticosteroids (OR = 1.69, 95% CI: 1.53–1.87); and PPIs reduced GIB risk (OR = 0.67, 95% CI: 0.62–0.74). Correlations between the DIOAC‐GIB and HAS‐BLED and DOAC scores were 0.5 for both ( p < 0.01). Conclusion: DIOAC‐GIB is a novel GIB‐risk model that incorporates pharmacodynamic OAC DDIs to assist clinicians and patients to determine a therapeutic plan while accounting for GIB risk. DIOAC‐GIB correlates with other bleeding risk scores and may help identify high‐risk patients who may benefit from tailored prescribing.